NOTICE OF UPGRADE

Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022

InvestoGain Australia
 

SEARCH LISTED COMPANY


Any AUS or NZ company

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH PRIVATE COMPANY


SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

COGSTATE LTD (CGS)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

 

Shareholder links

Our website ranking of CGS: rating 3
(3 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Automic Group
Level 5, 191 ST GEORGES TERRACE PERTH WA 6000
Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000CGS8
Address: Level 32 367 Collins Street Melbourne VIC 3000
Tel:  +61 3 9664 1300Fax: +61 3 9664 1301

Date first listed: 13/02/2004
Company Secretary: David Franks, Kristi Geddes
Sector: Health Care Equipment & Services Industry Group: XHJ
Activities: Commercialisation of computerized cognitive tests in clinical trials, concussion testing in sport, memory tests for clinical use, impairment testing in the workplace

News & Events

Expand this box to read and print

The suspension of trading in the securities of Cogstate Ltd will be lifted immediately following the release by CGS of an announcement regarding a response to an ASX Price Query.

24/02/2023

The company issues a response to ASX Price Query.

24/02/2023

Cogstate will release its half year report for the period ending 31 December 2022 (Appendix 4D) to ASX on 28 February 2023. For context, at 01 July 2022, Cogstate had contracted future revenue of $139.1m, of which it expected $29.7m to be recognized as revenue in FY23. Cogstate now expects approximately $5m of that FY23 contracted revenue to be recognized in FY24 ($3.3m from 1H23 and the remainder expected to impact 2H23). The company also noted more confidence in respect of Clinical Trials sales contracts that were expected to positively impact revenue and profitability in 2H23. Current expectations are that some of the larger value contracts are now expected to execute late in 2H23 and therefore will contribute less revenue and profit in FY23 than previously expected, with a larger revenue contribution in FY24, assuming execution. Cogstate advises it expects to report breakeven profit before tax for 1H23. Cogstate executed $27.9m of Clinical Trials sales contracts during 1H23, consistent with the result for the most recent half year of 2H22, taking contracted future revenue at 31 December 2022 to $146.7m (up from $139m at 30 June 2022). The Company provides the following updated guidance in respect of the full year ended 30 June 2023: 2H23 revenue expected to increase over 1H23, but FY23 revenue expected to be approximately 6-9% below FY22; EBITDA is expected to be in the range of 12-15% of revenue (4/Nov/22 guidance of 27-29%); EBIT is expected to be in the range of 6-8% of revenue (4/Nov/22 guidance of 20-24%); and Cash balance as at 31 December 2022 of $29m; expect positive operating cash flow for 2H23.

24/02/2023

The securities of Cogstate Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of CGS, pending the release of an announcement regarding a response to an ASX Price Query.

23/02/2023

listed entity carried for record purposes only

01/07/2004

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...

     


     

    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    16/05/2023Richard Mohs12,000$1.150
    USD
    $13,800
    07/03/2023Martyn Myer50,000$1.535$76,750
    02/03/2023Bradley O'Connor65,000$1.544$100,374
    14/09/2021Martyn Myer-250,000$1.771$442,733
    01/09/2021Kim Wenn11,686$1.726$20,170

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Martyn MyerChairman01/10/1999
    Bradley O'ConnorCEO12/05/2004
    Darren WatsonCFO01/02/2021
    Ingrid PlayerIndependent Director29/08/2019
    Kim WennIndependent Director30/11/2020
    Richard van den BroekNon Exec Director26/08/2010
    Richard MohsNon Exec Director20/01/2017

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    David DolbyNon Exec Director24/11/201325/01/2023
    Claire Newstead-SinclairCFO26/08/201001/02/2021
    Jane McAloonIndependent Director27/01/201721/10/2019
    George HunnewellCOO24/11/201601/05/2018
    David SimpsonNon Exec Director24/08/200425/10/2017
    Alan FinkelNon Exec Director12/05/201531/12/2015
    Rudy ChapaNon Exec Director22/08/201115/09/2014
    Michael WooldridgeNon Exec Director12/05/200402/07/2011
    Richard MorganNon Exec Director17/12/199902/07/2011
    Geoffrey BrookeNon Exec Director17/12/199927/10/2007
    Peter BickDirector, CEO17/12/199913/11/2005

    Date of first appointment, title may have changed.